CatalystFDA/Bio

ABBVIE’S JUVMO WINS FDA APPROVAL FOR PARKINSON’S DISEASE - SEEKINGALPHA

FDA approval of AbbVie's Juvmo for Parkinson's disease is a key biotech catalyst.

What changed

FDA approval of AbbVie's Juvmo for Parkinson's disease is a key biotech catalyst.

Why it matters

FDA approval of AbbVie's Juvmo for Parkinson's disease is a key biotech catalyst. — impact context not separately stored; see What changed.

Sources